T-DM1 is currently approved for the use in patients with unresectable or metastatic HER2-positive BC who were already pretreated with trastuzumab and taxane or relapsed during or within 6 months after completement of adjuvant therapy based on the results of the EMILIA trial [6]. Here, ERBB2 is linked to breast cancer.